Fate Therapeutics (FATE) Retained Earnings (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Retained Earnings data on file, last reported at -$1.6 billion in Q1 2026.

• Quarterly Retained Earnings fell 819745.03% year-over-year to -$1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 billion (down 819745.03% YoY) and the FY2025 annual result came in at $116000.0, down 56.72% from the prior year.
• Retained Earnings eased to -$1.6 billion in Q1 2026, from $116000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $1.6 billion in Q4 2023 to a low of -$1.6 billion in Q1 2026.
• A 5-year average of -$412.3 million and a median of -$646000.0 in 2023 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings jumped 250.36% — and 2026, when it tumbled 819745.03%.
• Tracing FATE's Retained Earnings over 5 years: stood at -$1.1 billion in 2022, then jumped by 250.36% to $1.6 billion in 2023, then slumped by 99.98% to $268000.0 in 2024, then sank by 56.72% to $116000.0 in 2025, then tumbled by 1349687.93% to -$1.6 billion in 2026.
• The last three Retained Earnings figures came in at -$1.6 billion (Q1 2026), $116000.0 (Q4 2025), and -$1.5 billion (Q3 2025), per Business Quant data.